R&D driven, AI-powered biopharma company, Sanofi, is to acquire Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM). Sanofi will pay US$129.00 per share…
France: Sanofi to acquire Blueprint for up to US$9.5bn
…
…






